Strategic positioning Vivasure Medical is now part of Haemonetics and operates from Galway, Ireland, with a focus on absorbable, patch-based large-bore vessel closure devices. This positions the company to leverage Haemonetics’ global reach and regulatory competencies to accelerate market access in Europe and the US.

Regulatory momentum Recent European CE mark approval for the PerQseal Elite and ongoing U.S. IDE PATCH pivotal study indicate active regulatory progression. Target opportunities exist with healthcare providers seeking compliant, innovative closures for large-bore endovascular procedures.

Product differentiation Focused on fully absorbable, sutureless patch-based closures for large-bore vessels, with ongoing development of PerQseal Blue for venous closures. This unique value proposition can be pitched to interventional centers looking to reduce foreign body load and recovery times.

Clinical validation Positive initial results from the PATCH pivotal study and participation in major conferences (TCT) highlight evidence generation and thought leadership. Leverage these outcomes to drive conversations with surgeons and procurement about safety, efficacy, and total cost of ownership.

Growth opportunities Funding history and large investor backing, along with Haemonetics’ involvement, suggest readiness for broader market penetration. Focus on expanding adoption through KOL engagement, strategic distributors, and payor-friendly reimbursement narratives to accelerate sales.